Search research articles
Contact Us
Filters
Showing results (321-330 of 408) with videos related to
Page
of 41
Sort By:
JTO Clinical and Research Reports
|
September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
Targeted Oncology
|
February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
Ping-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
April 10, 2016
Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention
Chia-Cheng Tseng, Chin-Chou Wang, Chang-Chun Hsiao, et al.
Frontiers in Oncology
|
October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
BMC Medical Education
|
January 7, 2017
Voluntary attendance of small-group brainstorming tutoring courses intensify new clerk's "excellence in clinical care": a pilot study
Ling-Yu Yang, Chia-Chang Huang, Hui-Chi Hsu, et al.
Frontiers in Computational Neuroscience
|
April 17, 2020
Inhibition of Long-Term Variability in Decoding Forelimb Trajectory Using Evolutionary Neural Networks With Error-Correction Learning
Shih-Hung Yang, Han-Lin Wang, Yu-Chun Lo, et al.
International Journal of Cancer
|
September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
The Journal of Infection
|
September 15, 2014
Aberrant Toll-like receptor 2 promoter methylation in blood cells from patients with pulmonary tuberculosis
Yung-Che Chen, Chang-Chun Hsiao, Chung-Jen Chen, et al.
Thoracic Cancer
|
July 24, 2024
Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients
Po-Ju Chen, Po-Chen Lai, Yueh-Chien Lu, et al.
Page
of 41
Search research articles
Search
Showing results (321-330 of 408) with videos related to
Sort By:
Page
of 41
JTO Clinical and Research Reports
|
September 30, 2021
Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With <i>EGFR</i> Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Daniel Shao Weng Tan, Wu-Chou Su, et al.
Targeted Oncology
|
February 22, 2023
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
Ping-Chih Hsu, Suey-Haur Lee, Li-Chung Chiu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|
April 10, 2016
Time courses and value of circulating microparticles in patients with operable stage non-small cell lung cancer undergoing surgical intervention
Chia-Cheng Tseng, Chin-Chou Wang, Chang-Chun Hsiao, et al.
Frontiers in Oncology
|
October 19, 2023
Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
Ping-Chih Hsu, Chun-Yao Huang, Yu-Ching Lin, et al.
Therapeutic Advances in Medical Oncology
|
August 11, 2021
First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer
Allen Chung-Cheng Huang, Chi-Hsien Huang, Jia-Shiuan Ju, et al.
BMC Medical Education
|
January 7, 2017
Voluntary attendance of small-group brainstorming tutoring courses intensify new clerk's "excellence in clinical care": a pilot study
Ling-Yu Yang, Chia-Chang Huang, Hui-Chi Hsu, et al.
Frontiers in Computational Neuroscience
|
April 17, 2020
Inhibition of Long-Term Variability in Decoding Forelimb Trajectory Using Evolutionary Neural Networks With Error-Correction Learning
Shih-Hung Yang, Han-Lin Wang, Yu-Chun Lo, et al.
International Journal of Cancer
|
September 24, 2021
Afatinib treatment in a large real-world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Chi-Hsien Huang, Jia-Shiuan Ju, Tzu-Hsuan Chiu, et al.
The Journal of Infection
|
September 15, 2014
Aberrant Toll-like receptor 2 promoter methylation in blood cells from patients with pulmonary tuberculosis
Yung-Che Chen, Chang-Chun Hsiao, Chung-Jen Chen, et al.
Thoracic Cancer
|
July 24, 2024
Association between exposure to organophosphate flame retardants and epidermal growth factor receptor expression in lung cancer patients
Po-Ju Chen, Po-Chen Lai, Yueh-Chien Lu, et al.
Page
of 41